Nimotuzumab, which is a humanized EGFR-optimized antibody, increased the 1-year survival rate of PCa patients by 2-fold in a phase II trial randomized (gemcitabine plus nimotuzumab vs. gemcitabine plus placebo) [113]. This evidence concerns the gene EGFR and posterior cortical atrophy.